{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:18:07Z","timestamp":1787811487086,"version":"build-2784847793"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Although daratumumab has been reported to significantly improve the prognosis of multiple myeloma (MM), its efficacy in patients with cytogenetically high-risk MM (HRMM) remains unclear. This meta-analysis aims to evaluate the effect of daratumumab on progression-free survival (PFS) and overall survival (OS) in patients with cytogenetically HRMM. Compared to treatment without daratumumab, treatment with daratumumab showed significant PFS (HR\u00a0=\u00a00.58,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&amp;lt;\u00a00.001) and OS (HR\u00a0=\u00a00.74,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.017) benefit in patients with cytogenetically HRMM. Subgroup analyses revealed similar PFS benefits for newly diagnosed MM (HR\u00a0=\u00a00.63,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&amp;lt;\u00a00.001), relapsed or refractory MM (HR\u00a0=\u00a00.53,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&amp;lt;\u00a00.001), subcutaneous daratumumab (HR\u00a0=\u00a00.69,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.038), and intravenous daratumumab (HR\u00a0=\u00a00.53,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&amp;lt;\u00a00.001). Meanwhile, daratumumab significantly improved PFS in patients with revised high cytogenetic risk (HR\u00a0=\u00a00.51,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&amp;lt;\u00a00.001). Another subgroup analysis revealed that daratumumab significantly improved PFS in both the one high-risk cytogenetic abnormality (HRCA) group (HR\u00a0=\u00a00.46,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&amp;lt;\u00a00.001) and the isolated gain\/amp(1q21) group (HR\u00a0=\u00a00.49,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&amp;lt;\u00a00.001), while no significant improvement in PFS was observed in the group with more than or equal to two HRCAs (HR\u00a0=\u00a00.64,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.212). However, sensitivity analysis showed that the beneficial OS is not robust. These results suggested that incorporating daratumumab into treatment regimens for patients with cytogenetic HRMM resulted in improved PFS. However, the effect of daratumumab on PFS may depend on HRCAs status. Additionally, the OS findings were suggestive of a potential benefit but require validation in future trials.\n                  <\/jats:p>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420251244272.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1787690","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:33:45Z","timestamp":1787808825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of daratumumab on patients with high-risk cytogenetic multiple myeloma: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Liang","family":"Su","sequence":"first","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minlan","family":"Ye","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Peng","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1669878","article-title":"Inflammatory markers from routine blood tests predict survival in multiple myeloma: a systematic review and meta-analysis","volume":"16","author":"Luo","year":"2025","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.36.5726","article-title":"Long-term analysis of the Ifm 99 trials for myeloma: cytogenetic abnormalities [T(4;14), del(17p), 1q gains] play a major role in defining long-term survival","volume":"30","author":"Avet-Loiseau","year":"2012","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.53.0329","article-title":"Combination of International Scoring System 3, high lactate dehydrogenase, and T(4;14) and\/or del(17p) identifies patients with multiple myeloma (Mm) treated with front-line autologous stem-cell transplantation at high risk of early Mm progression-related death","volume":"32","author":"Moreau","year":"2014","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0837-7","article-title":"Daratumumab: a review in relapsed and\/or refractory multiple myeloma","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"Cd38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26753","article-title":"Trial designs and endpoints for immune therapies in multiple myeloma","volume":"98","author":"Lancman","year":"2023","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103211","article-title":"Daratumumab-based induction therapy for multiple myeloma: a systematic review and meta-analysis","volume":"159","author":"Chong","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (Candor): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (Candor): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02506-1","article-title":"Daratumumab plus lenalidomide\/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the Maia study","volume":"39","author":"Moreau","year":"2025","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-020-00948-5","article-title":"Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of Castor based on cytogenetic risk","volume":"13","author":"Weisel","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41408-020-00375-2","article-title":"Daratumumab, lenalidomide, and dexamethasone in relapsed\/refractory myeloma: a cytogenetic subgroup analysis of Pollux","volume":"10","author":"Kaufman","year":"2020","journal-title":"Blood Cancer J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (Griffin): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1815111","article-title":"Rapid complete remission after one cycle of isatuximab-based quadruplet regimen in 1q21-positive primary plasma cell leukemia: a case report","volume":"17","author":"Pang","year":"2026","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278888","article-title":"Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients","volume":"106","author":"Weinhold","year":"2021","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The Prisma 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clin Res Ed)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1354593","article-title":"Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis","volume":"15","author":"Su","year":"2024","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00403-024-02840-5","article-title":"Circulating biomarkers of oxidative stress in people with acne vulgaris: a systematic review and meta-analysis","volume":"316","author":"Su","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (Cassiopeia): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet (London England)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (Apollo): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (Maia): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (Pollux): a randomized, open-label, phase iii trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.10.007","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: updated analysis of Lepus","volume":"23","author":"Fu","year":"2023","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (Castor): a randomized, open-label, phase iii trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the Candor study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41408-024-01088-6","article-title":"Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in Griffin","volume":"14","author":"Chari","year":"2024","journal-title":"Blood Cancer J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012539","article-title":"Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: Amarc 03-16","volume":"8","author":"Mollee","year":"2024","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1080\/10428194.2025.2561117","article-title":"Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed\/refractory multiple myeloma who received previous daratumumab treatment: Lynx study","volume":"66","author":"Bahlis","year":"2025","journal-title":"Leukemia Lymphoma"},{"key":"B38","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41408-025-01355-0","article-title":"Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: Auriga subgroup analyses","volume":"15","author":"Foster","year":"2025","journal-title":"Blood Cancer J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05958-8","article-title":"Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 Octans study","volume":"104","author":"Fu","year":"2025","journal-title":"Ann Hematol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (Alcyone): final analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"26","author":"Mateos","year":"2025","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 Cepheus trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34211","article-title":"Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: a meta-analysis of randomized controlled trials","volume":"128","author":"Chakraborty","year":"2022","journal-title":"Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","article-title":"Emerging agents and regimens for multiple myeloma","volume":"13","author":"Yang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1769281","article-title":"Modulating Cd38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective","volume":"17","author":"Horenstein","year":"2026","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016829","article-title":"Molecular and immunological determinants of long-term survival in multiple myeloma","volume":"9","author":"Kasomva","year":"2025","journal-title":"Blood Adv"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01253","article-title":"Co-occurrence of cytogenetic abnormalities and high-risk disease in newly diagnosed and relapsed\/refractory multiple myeloma","volume":"43","author":"Kaiser","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-025-01253-5","article-title":"Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Souto Filho","year":"2025","journal-title":"Blood Cancer J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase iii non-inferiority Columba study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"Usmani","year":"2022","journal-title":"Haematologica"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101168","article-title":"Chromosomal defects in multiple myeloma","volume":"64","author":"Clarke","year":"2024","journal-title":"Blood Rev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41408-022-00647-z","article-title":"Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group","volume":"12","author":"Mosquera Orgueira","year":"2022","journal-title":"Blood Cancer J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02654-y","article-title":"Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders","volume":"39","author":"Zanwar","year":"2025","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02677-5","article-title":"The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed\/refractory multiple myeloma: A systematic review and meta-analysis of randomized controlled trials","volume":"39","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Leukemia"},{"key":"B54","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the Nci multiple myeloma steering committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024371","article-title":"Evidence meta-analysis: Evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01286-w","article-title":"Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: A report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group","volume":"15","author":"Lu","year":"2025","journal-title":"Blood Cancer J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1787690\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:33:46Z","timestamp":1787808826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1787690\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2026.1787690"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1787690","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1787690"}}